1995 - Frankfurt - Germany

1995 - Frankfurt - Germany

Friday June 5
09:00-09:45 Registration and coffee
09:45-10:00 Welcome and Introduction
Morning program Chair: Jon Wakefield
10:00-10:20 Jon Wakefield Bayesian individualization via sampling-based methods
10:20-10:40 J Bennett, L Lacey, K Koch, A Bye Determination of the population pharmacokinetics of bismuth from GR122311X in healthy volunteers using the gibbs sampler bayesian method
10:40-11:00  L Harnisch, W Weber Population approach to nonlinear pharmacokinetics of a new drug under development
11:00-11:20 NJ Bruce, AH Thomson, HL Elliott Population pharmacokinetics of tacrolimus in liver transplant patients
11:20-11:40 M Karlsson, P Milligan, D Nichols Determination of relative potency for drug and metabolite in vivo
11:40-12:00 N Jonsson, JR Wade, G Almqvist, M Karlsson Discrimination between rival dosing histories
12:00-13:45 Lunch
Afternoon program PK/PD Chair: Leon Aarons:
13:45-14:10 D Hille, R Bruno, S Durrleman, LB Sheiner Relationship between the pharmacokinetics and the pharmacodynamics of taxotere in cancer patients
14:10-14:35 K Fattinger, D Verotta, HC Porchet, A Munafo, J-Y le Cotonnec, LB Sheiner Pharmacokinetic/-dynamic modeling of a bivariate control system: luteinizing hormone and testosterone response to GnRH antagonist antide
14:35-14:55 C Laveille, N Frey, G Lerebours, G Resplandy, R Jochemsen Population pharmacokinetic-pharmacodynamic of a new specific bradycardic agent: S-16257
14:55-15:15 S Marshall, HL Elliott, PA Meredith Prediction of simvastatin pharmacological response: a population analysis
15:15-15:45 Coffee break
Afternoon session II Population Toxicokinetics and Scaling from animal to man Chair: Eliane Fuseau
15:45-16:05 P Burtin, J van Bree, F Mentre, S Hensel, JL Steimer A prospective evaluation of sparse sampling for toxicokinetics in the course of drug development
16:05-16:25 V Cosson, E Fuseau, C Efthymiopoulos, A Bye From animal to man
16:25-16:45 W Weber, L Harnisch, M Zimmer, P Crause, B Katgely Optimization of a ''first dose in man study'' using a NONMEM model for mammals
16:45 - 17:30 Discussions and questions Chair: Lutz Harnisch
16:45-17:00 F Keller, D Zellner, T Frankewitsch, M Giehl  Population kinetics and individual drug dosage adjustment
17:30-18:30 Poster session I, Software demonstrations
20:00-24:00 Social Evening

Saturday June 10
Tutorial I Chair: France Mentré
09:30-09:45 H Hassani Stochastic model in the analysis of migraine data
09:45-10:30 F Rombout An industrial perspective: practical stages in model development
10:30-11:00 Coffee break
Tutorial II Chair: Gudrun Wallenstein
11:00-11:45 L Aarons Practical experience and issues in designing and performing population pharmacokinetic/pharmacodynamic studies
11:45-12:00 H-J Röthig, W Weber Closing remarks
12:00-14:00 Poster session II, software demonstrations

Posters Friday (group I)

Study design
1. D Breilh, C Pobel, MC Saux
Non linear pharmacokinetics of ethanol Analysis of patients with NONMEM. study I
2. D Breilh, C Pobel, MC Saux
Non linear pharmacokinetics of ethanol Population model with NONMEM after an optimal sampling duration. study II
3. B Charpiat, V Broant, G Tissier, JM Sab, P Maire, RW Jelliffe
How many patients and blood levels for population pharmacokinetic analysis? a study with a one compartment model
4. AC Falcao, MM Fernandez de Gatta, A Dominguez-Gil, JM Lanao
Sampling strategies for population analysis: a theoretical study to support practical results obtained with caffeine in premature neonates
5. NS Houwing, F Rombout
Population pharmacokinetics: effect of sampling scheme on parameter estimation

Drug development
6. G Lockwood, G Maier
The use of population pharmacokinetic approaches to aid in the assessment of bioequivalence for a highly variable drug
7. M Looby, U Wuenscher, M Weiss
NONMEM in destructive sampling experiments: experiences with the toxicokinetics of dibromchloromethane
8. F Mesnil, F Mentre, C Dubruc, A Mallet
Population pharmacokinetics analysis of mizolastine: estimation with NPML and validation
9. P Milligan, M Karlsson, D Nichols
High variability compounds - high risk for developers?
10. JPR Monteleone, NHG Holford
Modeling interoccasion variability in toxicokinetics and toxicodynamics

Data rich situations
11. R Schoemaker, A Cohen
Estimation of kinetic/dynamic curves with insufficient information for each individual using non-linear mixed effect modelling
12. J Wade, B-M Emanuelsson, LL Gustafsson, M Karlsson
A population approach enables the characterisation of saturable protein binding for Ropivacaine
13. W Weber, L Harnisch, M Zimmer, C Rokitta, P Mendes
New evidence for a triexponential disposition of Cefotaxim

Software demonstrations
1. M Tod
An algorithm for the estimation of optimal sampling times in pharmacokinetics by the ed, eid and api criteria
2. S Urien
MP2 (Micropharm population): a Windows application for population pharmacokinetics
3. J Wakefield, G Strehlau
Software product POPKAN; population pharmacokinetic modelling and analysis

Posters Saturday (group II)

14. D Breilh, C Pobel, C Roth, MC Saux, G Janvier
Sufentanyl Pharmacokinetic-pharmacodynamic modeling (PK/PD) on NONMEM in 10 patients with coronary surgery
15. MJ du Preez, JH Botha, ML McFadyen, M Adhikari Effect concentration relationships of theophylline in apnoea of prematurity
16. S Rietbrock, S Harder, H Baas
Influence of apomorphine on the PK/PD-relationship of levodopa: two-step versus NONMEM analysis

17. D Breilh, C Pobel, P Rispal, MC Saux
Population of vancomycine with continuous infusion administered in neutropenic patients modeling on NPEEM2-NONMEM-P-PHARM
18. J Bres, D Cupissol, J Nouguier-Soule, C Gestin-Boyer, Ü Büttner, B Palomba
Population distribution of platinum pharmacokinetic parameters for dosage recommendations of CDDP and adaptive control during the course of therapy, using different softwares
19. MT Mateu-Garcia, JJ Porez-Ruixo, VG Casabo-Alos, NV Jimenez-Torres Apache II as predictor of gentamicin pharmacokinetic parameters in critical ill patients
20. H Peyriere, J Bres, D Hillaire-Buys
Performance evaluation of three softwares for bayesian predictions of teicoplanin pharmacokinetic parameters: Apis Micropharm, PKS Abbott
21. D Santos Buelga, MF Delgado Iribarnegaray, MJ Garca, MJ Otero, A Falcao, A Dominguez-Gil
Carbamazepine population pharmacokinetics in children
22. M Tod, C Padoin, C Minozzi, J Cougnard, O Petitjean
A population pharmacokinetic study of isepamicin in ICU patients

23. LS Murray, DI Jodrell, JG Morrison, AW Kelman, DJ Kerr, B Whiting, SB Kaye
A population approach to predicting post-treatment levels of epirubicin in patients with advanced breast cancer
24. M Sandström, A Freijs, R Larsson, P Nygren, J Bergh, M-L Fjollskog, M Karlsson
Lack of relationship between systemic exposure for the component drugs of the FEC regimen in breast cancer patients
24. B Tranchand, S Urien, CJ Ardiet Population pharmacokinetics of intravenous melphalan: NONMEM and MP2 analysis